|Bid||17.42 x 800|
|Ask||17.43 x 900|
|Day's range||17.27 - 17.68|
|52-week range||15.50 - 25.77|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||34.08|
|Earnings date||08 Feb 2022 - 14 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.77|
For more than a decade, growth stocks have been the talk of Wall Street. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022.
ALAMEDA, Calif., January 18, 2022--Exelixis, Inc. (Nasdaq: EXEL) today announced results for cabozantinib (CABOMETYX®) in combination with immunotherapies in patients with advanced colorectal cancer, including encouraging data from cohort 16 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic colorectal cancer who were previously treated with fluoropyrimidine-containing chemotherapy. Results from cohort 2 of the phase 2 CAMILLA trial of c
Exelixis (EXEL) provides preliminary results for the fourth quarter and outlines priorities for 2022.